» Articles » PMID: 30280491

Clinical and Biological Relevance of Genetic Alterations in Pediatric T-cell Acute Lymphoblastic Leukemia in Taiwan

Overview
Date 2018 Oct 4
PMID 30280491
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The leukemogenesis of T-cell acute lymphoblastic leukemia (T-ALL) involves multistep processes of genetic alterations. We aimed to determine the genetic alterations including common fusion transcripts, overexpression of T-cell transcription factor oncogenes, and deletion or mutation of targeted genes in pediatric T-ALL in Taiwan as well as their impact on outcomes in those treated with the Taiwan Pediatric Oncology Group-ALL-2002 protocol.

Procedure: Between 1995 and 2015, bone marrow samples obtained from 102 children aged <18 years consecutively diagnosed with T-ALL were examined. Thirty-two genetic alterations were examined by reverse transcription polymerase chain reaction (PCR) assays-PCR-based assays-followed by direct sequencing, real time quantitative PCR with TaqMan assays, or multiplex ligase probe amplification.

Results: TAL1 overexpression, CDKN2A/2B deletions, and NOTCH1 mutation were the most frequent aberrations while none had NF1, SUZ12 deletion, JAK1 or JAK2 mutations, or NUP214-ABL1 fusion in our cohort. The most frequent cooperating occurrence of genetic alterations included CDKN2A/2B and MTAP, MTAP and CDKN2B, LEF1 and PTPN2, and HOX11L2 and PHF6 mutation/deletion. NOTCH1 mutations conferred a favorable overall survival, whereas SIL-TAL1 fusion, TAL overexpression, LEF1 deletion, and PHF6 deletion/mutation were associated with an inferior outcome. By multivariate analysis, PHF6 mutation/deletion was the only independent predictor for inferior overall survival.

Conclusions: The present study showed that the frequencies of genetic alterations in Taiwanese children with T-ALL differed considerably from those reported in Western countries. PHF6 mutation/deletion was an independently adverse predictor.

Citing Articles

Integrated analysis of transcriptome and genome variations in pediatric T cell acute lymphoblastic leukemia: data from north Indian tertiary care center.

Singh M, Sharma P, Bhatia P, Trehan A, Thakur R, Sreedharanunni S BMC Cancer. 2024; 24(1):325.

PMID: 38459434 PMC: 10924344. DOI: 10.1186/s12885-024-12063-6.


Spectrum and clinical features of gene mutations in Chinese pediatric acute lymphoblastic leukemia.

Shen D, Liu L, Xu X, Song H, Zhang J, Xu W BMC Pediatr. 2023; 23(1):62.

PMID: 36739388 PMC: 9898934. DOI: 10.1186/s12887-023-03856-y.


Genomic landscape of T-cell lymphoblastic lymphoma.

Li Z, Song Y, Zhang M, Wei Y, Ruan H Chin J Cancer Res. 2022; 34(2):83-94.

PMID: 35685993 PMC: 9086577. DOI: 10.21147/j.issn.1000-9604.2022.02.03.


Integrated genomic analyses identify high-risk factors and actionable targets in T-cell acute lymphoblastic leukemia.

Zhu H, Dong B, Zhang Y, Wang M, Rao J, Cui B Blood Sci. 2022; 4(1):16-28.

PMID: 35399540 PMC: 8974951. DOI: 10.1097/BS9.0000000000000102.


Mutations in Hematologic Malignancies.

Kurzer J, Weinberg O Front Oncol. 2021; 11:704471.

PMID: 34381727 PMC: 8350393. DOI: 10.3389/fonc.2021.704471.